Skip to content

EUREKA PHARMA

Active Private limited companyfounded 2005active for 21 yearsHarelbeeksestraat 81, 8520 KuurneKBO/BCE: BE 0877.239.492

Board

2 directors, last change in 2014
Director, permanent representative
since 02-02-2014 term without a fixed end
listed in the 2025 annual accounts, filed on 30-06-2026
Director, permanent representative
since 02-02-2014 term without a fixed end
listed in the 2025 annual accounts, filed on 30-06-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Each director alone
deed of 22-01-2026
Permanent representatives 2
Permanent representative, for
appointed by deed of 06-03-2014
Permanent representative, for
appointed by deed of 06-03-2014

Office holders in the KBO →

Mandates through the years

2 names, the dashed line is today

Manager

Manager
Board
Mandates as a list
    • Manager, from 02-02-2014 to date
    • Manager, from 02-02-2014 to date
With Starter you also see 2 former office holders in the mandate history. See plans →

Control

Shareholders
,
This company
EUREKA PHARMA
Equity €1.6m
Profit €15,385 in 2025

Capital

Contribution
€50,000
Source
2025 annual accounts

Articles of association

deed of 22-01-2026 (in Dutch)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
Artikel 10-Overdracht of overgang van de aandelen, datum kennisgeving overdragende aandeelhouder
Bepaald door deskundigen, Artikel 10.2.5 mutatis mutandis, stemrechten desbetreffende aandelen niet geschorst gedurende periode voorgenomen Controlewijziging to…
In principe aangeboden prijs kandidaat-overnemer zoals vermeld in kennisgeving, bestuursorgaan en Begunstigde Aandeelhouder(s)
Behoudens andersluidende overeenkomst Artikel 10.2.5 mutatis mutandis, goedkeuring bij overlijden/ontbinding rechtspersoon-aandeelhouder
Voorafgaand aan Controlewijziging, Artikel 11.1
Door deskundigen mutatis mutandis Artikel 10.2.5, na Controlewijziging
Andere aandeelhouders hebben volgrecht hun aandelen aan deze derden over te dragen tegen prijs en modaliteiten als hierna bepaald, volgrecht
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
“Artikel 23- Organisatie en bijeenroeping Ieder jaar wordt een gewone algemene vergadering van aandeelhouders gehouden op de zetel…”

Shareholders

Stated in the deed deed of 22-01-2026 ↗
  • 2,500 shares
  • 2,500 shares

Capital transactions

Capital over time
  1. 22-01-2026 Converted to unavailable equity
  2. 22-01-2026 Converted to unavailable equity · €55,000

Next steps